Kynamro mipomersen regulatory update

Sanofi said its Genzyme Corp. subsidiary submitted an MAA to EMA for Kynamro mipomersen to treat homozygous and severe heterozygous familial hypercholesterolemia. Genzyme expects to submit an applica...